Financials WntResearch AB

Equities

WNT

SE0022239901

Biotechnology & Medical Research

End-of-day quote NORDIC GROWTH MARKET 06:00:00 2024-07-10 pm EDT 5-day change 1st Jan Change
16.29 SEK -3.04% Intraday chart for WntResearch AB +6.47% +77.07%

Valuation

Fiscal Period: December 2023 2024 2025 2026
Capitalization 1 36.89 141.1 - -
Enterprise Value (EV) 1 36.89 142.1 38.08 141.1
P/E ratio -83.6 x - - -
Yield - - - -
Capitalization / Revenue - - 1.48 x -
EV / Revenue - - 0.4 x -
EV / EBITDA - -3.13 x 0.53 x -20.2 x
EV / FCF - -3.02 x 0.49 x -
FCF Yield - -33.1% 202% -
Price to Book - - - -
Nbr of stocks (in thousands) 4,010 8,661 - -
Reference price 2 9.200 16.29 16.29 16.29
Announcement Date 2/29/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2023 2024 2025 2026
Net sales 1 - - 95.1 -
EBITDA 1 - -45.4 72.1 -7
EBIT 1 - -45.7 72.1 -7
Operating Margin - - 75.81% -
Earnings before Tax (EBT) - - - -
Net income -32.47 - - -
Net margin - - - -
EPS -0.1100 - - -
Free Cash Flow 1 - -47 77 -
FCF margin - - 80.97% -
FCF Conversion (EBITDA) - - 106.8% -
FCF Conversion (Net income) - - - -
Dividend per Share - - - -
Announcement Date 2/29/24 - - -
1SEK in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - -
EBITDA 1 -11.8 -11.3 -10.9
EBIT 1 -11.9 -11.4 -11
Operating Margin - - -
Earnings before Tax (EBT) - - -
Net income - - -
Net margin - - -
EPS - - -
Dividend per Share - - -
Announcement Date - - -
1SEK in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2023 2024 2025 2026
Net Debt 1 - 1 - -
Net Cash position 1 - - 103 -
Leverage (Debt/EBITDA) - -0.022 x - -
Free Cash Flow 1 - -47 77 -
ROE (net income / shareholders' equity) - - - -
ROA (Net income/ Total Assets) - - - -
Assets - - - -
Book Value Per Share - - - -
Cash Flow per Share - - - -
Capex - - - -
Capex / Sales - - - -
Announcement Date 2/29/24 - - -
1SEK in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. WNT Stock
  4. Financials WntResearch AB